Previous 10 | Next 10 |
Pamiparib, a potent and selective PARP1 and PARP2 inhibitor, demonstrated meaningful and durable efficacy in patients with advanced HER2-negative breast cancer Pamiparib showed numerically higher progression-free survival in patients with gastric cancer compared to placebo, al...
BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysis BRUKINSA was associated with a statistically significant lower risk of atrial fibrillation or flutter Company to host investor call and webcast on Friday, ...
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreemen...
Tislelizumab combined with chemotherapy demonstrated a statistically significant improvement in progression-free survival at the interim analysis Safety findings of tislelizumab were consistent with known risks BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global ...
Scheduled to present results and trial designs on five therapeutic candidates from 13 clinical trials across eight types of cancer Featuring three anti-PD-1 combinations and the continuing evaluation of next-generation BTK inhibitor zanubrutinib BeiGene, Ltd. (NA...
Under priority review, the FDA has accepted BeiGene's (BGNE) supplemental new drug application (sNDA) for Brukinsa (zanubrutinib) for the treatment of adult patients with marginal zone lymphoma ((MZL)) who have received at least one prior anti-CD20-based therapy and granted priority review.Th...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for BRUKINSA ...
Are These The Best Biotech Stocks To Buy Now? It is a known fact for investors that biotech stocks are historically volatile in the stock market. Often, the value of the stock is speculative and based on the promise of a new drug or treatment. Until the drug proves viable, recei...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results from its broad hematology program will be presented at the 26 th European Hematology Association ...
The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian ...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...